The Cystic Fibrosis Transmembrane Conductance Regulator Gene (CFTR) Is under Post-Transcriptional Control of microRNAs: Analysis of the Effects of agomiRNAs Mimicking miR-145-5p, miR-101-3p, and miR-335-5p.

Publisher: MDPI AG Country of Publication: Switzerland NLM ID: 101652294 Publication Model: Electronic Cited Medium: Internet ISSN: 2311-553X (Electronic) Linking ISSN: 2311553X NLM ISO Abbreviation: Noncoding RNA Subsets: PubMed not MEDLINE

Original Publication: Basel, Switzerland : MDPI AG, [2015]-

(1) Background: MicroRNAs are involved in the expression of the gene encoding the chloride channel CFTR (Cystic Fibrosis Transmembrane Conductance Regulator); the objective of this short report is to study the effects of the treatment of bronchial epithelial Calu-3 cells with molecules mimicking the activity of pre-miR-145-5p, pre-miR-335-5p, and pre-miR-101-3p, and to discuss possible translational applications of these molecules in pre-clinical studies focusing on the development of protocols of possible interest in therapy; (2) Methods: CFTR mRNA was quantified by Reverse Transcription quantitative Polymerase Chain Reaction (RT-qPCR). The production of the CFTR protein was assessed by Western blotting; (3) Results: The treatment of Calu-3 cells with agomiR-145-5p caused the highest inhibition of CFTR mRNA accumulation and CFTR production; (4) Conclusions: The treatment of target cells with the agomiR pre-miR-145-5p should be considered when CFTR gene expression should be inhibited in pathological conditions, such as polycystic kidney disease (PKD), some types of cancer, cholera, and SARS-CoV-2 infection.

Biochem Pharmacol. 2018 Apr;150:293-304. (PMID: 29475061)
Ital J Pediatr. 2020 Oct 6;46(1):143. (PMID: 33023602)
Indian J Pharmacol. 2012 Sep-Oct;44(5):619-23. (PMID: 23112425)
Mol Med Rep. 2020 Dec;22(6):5282-5292. (PMID: 33174029)
Int J Mol Sci. 2022 Aug 19;23(16):. (PMID: 36012615)
Molecules. 2020 Apr 05;25(7):. (PMID: 32260566)
Int J Environ Res Public Health. 2020 May 06;17(9):. (PMID: 32384765)
Perspect Clin Res. 2016 Apr-Jun;7(2):68-74. (PMID: 27141472)
Crit Care Res Pract. 2010;2010:. (PMID: 20948883)
J Cell Mol Med. 2020 Jul;24(13):7301-7312. (PMID: 32463592)
PLoS One. 2022 Nov 18;17(11):e0277096. (PMID: 36399482)
Am J Respir Crit Care Med. 2018 Mar 1;197(5):632-643. (PMID: 29232160)
Oncol Rep. 2015 May;33(5):2227-34. (PMID: 25738998)
FEBS Lett. 2020 Dec;594(23):4085-4108. (PMID: 33113586)
Data Brief. 2021 Jan 09;35:106718. (PMID: 33553515)
Front Genet. 2019 May 16;10:478. (PMID: 31156715)
Am J Respir Cell Mol Biol. 2013 Oct;49(4):544-51. (PMID: 23646886)
J Invest Dermatol. 2019 Mar;139(3):528-534. (PMID: 30686578)
Pathol Res Pract. 2020 Apr;216(4):152872. (PMID: 32107086)
Development. 2005 Nov;132(21):4653-62. (PMID: 16224045)
Nat Rev Drug Discov. 2017 Mar;16(3):203-222. (PMID: 28209991)
Nat Commun. 2023 Jan 10;14(1):132. (PMID: 36627352)
Transl Cancer Res. 2022 Mar;11(3):436-443. (PMID: 35402186)
Mol Ther Nucleic Acids. 2019 Dec 6;18:748-763. (PMID: 31733592)
J Pharmacol Sci. 2022 Apr;148(4):369-376. (PMID: 35300812)
J Cell Sci. 2018 Aug 17;131(16):. (PMID: 30030371)
Proc Natl Acad Sci U S A. 2012 Aug 14;109(33):13362-7. (PMID: 22853952)
Oncogene. 2016 Aug 11;35(32):4179-87. (PMID: 26751771)
Pathogens. 2022 Mar 17;11(3):. (PMID: 35335691)
Biomedicines. 2021 Jan 26;9(2):. (PMID: 33530577)
J Immunol. 2013 Apr 1;190(7):3354-62. (PMID: 23436935)
Mol Ther. 2020 Apr 8;28(4):1190-1199. (PMID: 32059764)
Kidney Int. 1996 Jul;50(1):208-18. (PMID: 8807590)
Cells. 2022 Apr 15;11(8):. (PMID: 35456026)
PLoS One. 2011;6(10):e26601. (PMID: 22028919)
Dis Mon. 2020 May;66(5):100887. (PMID: 31582186)
J Adv Res. 2020 Aug 29;28:127-138. (PMID: 33364050)
Biomed Pharmacother. 2017 Oct;94:820-826. (PMID: 28802235)
BMC Cancer. 2022 Nov 8;22(1):1151. (PMID: 36348305)
Virulence. 2016 Oct 2;7(7):789-805. (PMID: 27222028)
Eur J Med Chem. 2021 Jan 1;209:112876. (PMID: 33127171)
PLoS One. 2012;7(11):e50837. (PMID: 23226399)
Cell. 2005 Jul 15;122(1):9-12. (PMID: 16009127)
Antimicrob Agents Chemother. 2015 Jan;59(1):599-608. (PMID: 25385103)
Nat Rev Genet. 2004 Jul;5(7):522-31. (PMID: 15211354)
Lancet. 2017 Feb 18;389(10070):709-717. (PMID: 28087069)
Clin Exp Nephrol. 2021 Sep;25(9):944-952. (PMID: 34057612)
PLoS One. 2008;3(10):e3420. (PMID: 18923704)
Cancer Manag Res. 2020 Jun 08;12:4261-4270. (PMID: 32606923)
Mol Ther. 2019 Feb 6;27(2):442-455. (PMID: 30595527)
J Am Soc Nephrol. 2008 Jul;19(7):1300-10. (PMID: 18385427)
J Cyst Fibros. 2023 Mar;22 Suppl 1:S17-S22. (PMID: 36621373)
Biochem J. 2011 Aug 15;438(1):25-32. (PMID: 21689072)
Am J Respir Crit Care Med. 2019 Jun 1;199(11):1443-1444. (PMID: 30811944)
Toxins (Basel). 2022 Mar 18;14(3):. (PMID: 35324722)
BMC Genomics. 2014 Nov 21;15:1010. (PMID: 25416156)
Genomics Proteomics Bioinformatics. 2012 Oct;10(5):246-53. (PMID: 23200134)
Vaccines (Basel). 2021 Sep 23;9(10):. (PMID: 34696164)
Molecules. 2017 Dec 29;23(1):. (PMID: 29286300)

FFC#7/2016 Cystic Fibrosis Research Foundation; FISR2020IP_04128 FISR-MUR; Project CIB-Unife-2020 Interuniversity Consortium for Biotechnology; FAR-AF-Unife-2018 University Fund for Scientific Research FAR; FAR-AF-Unife-2019 University Fund for Scientific Research FAR; FAR-AF-Unife-2020 University Fund for Scientific Research FAR

Keywords: CFTR; agomiRNAs; miR-145-5p; miRNA therapy; microRNAs; pre-miRNAs

Date Created: 20230427 Latest Revision: 20230501

20231215

PMC10146138

10.3390/ncrna9020029

37104011